Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA. Treatment patterns and health outcomes in platinum-refractory or platinum-resistant ovarian cancer: a retrospective medical record review. Int J Gynecol Cancer. 2018 May;20(4):738-48. doi: 10.1097/IGC.0000000000001222
Alverez SA, Bae-Jump V, Havrilesky LJ, Calingaert B, Clarke-Pearson ADL, Soper JT, Gehrig PA. Attitudes regarding the use of hematopoietic colony-stimulating factor utilization and maintenance of relative dose intensity among gynecologic oncologists. Int J Gynecol Cancer. 2009 Apr;19(3):447-54.
Lancaster JM, Sayer RA, Blanchette C, Calingaert B, Konidari I, Gray J, Schildkraut J, Schomberg DW, Marks JR, Berchuck A. High expression of insulin-like growth factor binding protein–2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels. Int J Gynecol Cancer. 2006 Jul 1;16(4):1529-35.
Lanza FL, Sontag SJ, Ciociola AA, Sykes DL, Heath AT, McSorley DJ. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter. 1998 Sep;3(3):212-21.
Graham DY, Breiter JR, Ciociola AA, Sykes DL, McSorley DJ. An alternative non-macrolide, non-imidazole treatment for curing helicobacter pylori and duodenal ulcers: ranitidine bismuth citrate plus amoxicillin. Helicobacter. 1998 Jun;3(2):125-31.